Background: Patients with advanced melanoma who progress after treatment with immune checkpoint-inhibitors (ICI) and BRAF-/MEK-inhibitors (if mutated) have no remaining effective treatment options. The presence of CD1c (BDCA-1) and CD141 (BDCA-3) myeloid dendritic cells (myDC) in the tumor microenvironment correlates with pre-existing immune recognition and responsiveness to immune checkpoint blockade. The synthetic saponin-based immune adjuvant AS01 enhances adaptive immunity through the involvement of myDC.

Methods: In this first-in-human phase I clinical trial, patients with metastatic melanoma refractory to ICI and BRAF-/MEK inhibitors (when indicated) were recruited. Patients received an intravenous administration of low-dose nivolumab (10 mg, every 2 weeks) plus an intratumoral (IT) administration of 10 mg ipilimumab and 50 µg (0.5 mL) AS01 (every 2 weeks). All myDC, isolated from blood, were injected on day 2 into the same metastatic lesion. Tumor biopsies and blood samples were collected at baseline and repeatedly on treatment. Multiplex immunohistochemistry (mIHC) was performed on biopsy sections to characterize and quantify the IT and peritumoral immune cell composition.

Results: Study treatment was feasible and well tolerated without the occurrence of unexpected adverse events in all eight patients. Four patients (50%) obtained a complete response (CR) in the injected lesions. Of these, two patients obtained an overall CR, and one patient a partial response. All responses are ongoing after more than 1 year of follow-up. One additional patient had a stable disease as best response. The disease control rate was 50%. Median progression-free survival and overall survival were 24.1 and 41.9 weeks, respectively. Baseline tumor biopsies from patients who responded to treatment had features of T-cell exclusion. During treatment, there was an increased T-cell infiltration, with a reduced mean distance between T cells and tumor cells. Peripheral blood immune cell composition did not significantly change during study treatment.

Conclusions: Combining an intratumoral injection of CD1c (BDCA-1) and CD141 (BDCA-3) myDC with repeated IT administration of ipilimumab and AS01 and systemic low-dose nivolumab is safe, feasible with promising early results, worthy of further clinical investigation.

Trial Registration Number: ClinicalTrials.gov identifier NCT03707808.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10806541PMC
http://dx.doi.org/10.1136/jitc-2023-008148DOI Listing

Publication Analysis

Top Keywords

intratumoral administration
8
adjuvant as01
8
bdca-3 myeloid
8
myeloid dendritic
8
dendritic cells
8
patients
8
advanced melanoma
8
cd1c bdca-1
8
bdca-1 cd141
8
cd141 bdca-3
8

Similar Publications

Revisiting hydrogen peroxide as radiosensitizer for solid tumor cells.

Radiother Oncol

December 2024

Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, 1090 Brussels, Belgium. Electronic address:

Background And Purpose: Tumor hypoxia is the principal cause of clinical radioresistance. Despite its established role as radiosensitizer, hydrogen peroxide (HO) encounters clinical limitations due to stability and toxicity concerns. Recent advancements in drug delivery combine HO with sodium hyaluronate (SH), enabling intratumoral administration of HO.

View Article and Find Full Text PDF

The basic requirements for the development of radiopharmaceuticals for radionuclide therapy of tumors include marked tumor-specific accumulation and long-term intratumoral retention. We have previously reported an indium-111 (In)-labeled thermoresponsive polymer (polyoxazoline (POZ)) that is soluble at body temperature with rapid clearance from normal tissues but self-aggregates in the tumor upon tumor heating treatment. POZ accumulated in the tumor via self-aggregation under hyperthermic conditions and was retained after stopping heat exposure.

View Article and Find Full Text PDF

Bacillus Calmette-Guerin (BCG) is the current standard of care for non-muscle invasive bladder cancer (NMIBC), but recurrence is common. Additional therapeutic options are a major unmet medical need for treating unresponsive patients. Stimulator of Interferon Genes (STING) plays a central role in mounting innate and adaptive immune responses to tumor cells, and activation of STING is a promising immunotherapeutic approach.

View Article and Find Full Text PDF

Intratumoral injections often lack visibility, leading to unpredictable outcomes such as incomplete tumor coverage, off-target drug delivery and systemic toxicities. This study investigated an ultrasound (US) and x-ray imageable thermosensitive hydrogel based on poloxamer 407 (POL) percutaneously delivered in a healthy swine model. The primary objective was to assess the 2D and 3D distribution of the hydrogel within tissue across three different needle devices and injection sites: liver, kidney, and intercostal muscle region.

View Article and Find Full Text PDF

Neutrophils in oncolytic virus immunotherapy.

Front Immunol

December 2024

Huayao Kangming Biopharmaceutical Co., Ltd, Shenzhen, China.

Oncolytic viruses have emerged as a highly promising modality for cancer treatment due to their ability to replicate specifically within tumors, carry therapeutic genes, and modulate the immunosuppressive tumor microenvironment through various mechanisms. Additionally, they show potential synergy with immune checkpoint inhibitors. A study report indicates that from 2000 to 2020, 49.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!